Variable | Population (n=2011) | SMR without SAD (n=592) | SADMR (n=1419) | P value |
Age | 69.7±13.9 | 68.2±14.2 | 70.4±13.8 | <0.01 |
BMI | 28.2±11.5 | 29.3±9.9 | 27.7±12.1 | 0.01 |
Female sex | 830 (41%) | 287 (48%) | 543 (38%) | <0.001 |
Hypertension | 1552 (77%) | 446 (75%) | 1106 (78%) | 0.21 |
Hyperlipidaemia | 1283 (64%) | 359 (61%) | 924 (65%) | 0.06 |
Coronary artery disease | 1327 (66%) | 392 (66%) | 935 (66%) | 0.89 |
Diabetes | 783 (39%) | 210 (35%) | 573 (40%) | 0.04 |
Atrial fibrillation | 1282 (64%) | 389 (66%) | 893 (63%) | 0.24 |
Atrial flutter | 293 (15%) | 92 (16%) | 201 (14%) | 0.43 |
Medications | ||||
Aspirin | 1829 (91%) | 533 (90%) | 1296 (91%) | 0.36 |
Cholesterol lowering agents | 1351 (67%) | 382 (65%) | 969 (48%) | 0.1 |
ACEi/ARB/ARNi | 1722 (86%) | 492 (83%) | 1230 (87%) | 0.04 |
Diuretics | 1919 (95%) | 555 (94%) | 1364 (96%) | 0.02 |
Betablockers | 1930 (96%) | 559 (95%) | 1371 (97%) | 0.02 |
CCB | 922 (46%) | 269 (45%) | 653 (46%) | 0.81 |
Antiarrhythmics | 1825 (91%) | 531 (90%) | 1294 (92%) | 0.29 |
Warfarin | 1021 (51%) | 311 (53%) | 710 (50%) | 0.31 |
DOAC | 662 (33%) | 177 (30%) | 485 (34%) | 0.06 |
NYHA class | 0.58 | |||
Class I | 170 (9%) | 41 (7%) | 130 (9%) | |
Class II | 629 (31%) | 185 (31%) | 445 (31%) | |
Class III | 888 (44%) | 278 (47%) | 609 (43%) | |
Class IV | 323 (16%) | 89 (15%) | 235 (17%) |
Significant p-values (<0.05) are highlighted in bold.
ACEi, ACE inhibitor; ARB, angiotensine receptor blocker; ARNi, angiotensine receptor-neprilysin inhibitor; BMI, body mass index; CCB, calcium channel blocker; DOAC, direct oral anticoagulant; NYHA, New York Heart Association; SAD, severe atrial dilation; SMR, secondary mitral regurgitation.